Liver insulin resistance and glucagon-stimulated hepatic glucose production are characteristics of the diabetic state. To determine the potential role of glucose toxicity in these abnormalities, we examined whether phlorizin treatment of streptozotocin-diabetic rats resulted in altered expression of genes involved in key steps of hepatic glucose metabolism. By inhibiting renal tubular glucose reabsorption, phlorizin infusion to diabetic rats induced normoglycaemia, did not significantly alter low circulating insulinaemia, but caused a marked decrease in hyperglucagonaemia. Glucokinase and L-type pyruvate kinase mRNA levels were reduced respectively by 90 % and 70 % in fed diabetic rats, in close correlation with changes in enzyme activities. Eighteen days of phlorizin infusion partially restored glucokinase mRNA and activity (40 % of control levels), but had no effect on L-type pyruvate kinase mRNA and activity. In contrast to the glycolytic enzymes, mRNA and activity of the gluconeogenic enzyme, phospoenolpyruvate carboxykinase were increased (10-and 2.2-fold, respectively) in fed diabetic rats. Phlorizin administration decreased phospoenolpyruvate carboxykinase mRNA to values not different from those in control rats, while phospoenolpyruvate carboxykinase activity remained 50 % higher than that in control rats. The 50 % rise in liver glucose transporter (GLUT2) mRNA and protein, produced by diabetes, was also corrected by phlorizin treatment.
Defects in insulin secretion and insulin action are major features of the pathogenesis of both Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes mellitus in man, and similar disturbances have been shown in animal models of diabetes. It is well-established that an initial defect in insulin secretion can lead to the development of insulin resistance [1] . The latter appears first in the liver, then in peripheral tissues of rats made diabetic by streptozotocin injection [2] . During the last decade, it has been recognized that chronic hyperglycaemia itself may play a pathogenic role in diabetes by maintaining a self-perpetuating cycle of metabolic deterioration and the concept of glucose toxicity has emerged [3, 4] . The first evidence presented was that hyperglycaemia per se may attenuate the secretory response of pancreatic islet cells to glucose in some animal models of diabetes [5] [6] [7] . It has been further demonstrated that chronic hyperglycaemia may impair the effects of insulin on glucose uptake by peripheral tissues [3, [8] [9] [10] [11] and on glucose production by the liver [10] .
It has been suggested that, in insulin-deficient rats, hyperglycaemia-induced peripheral insulin resistance involved a down-regulation of the glucose transporter isoform GLUT 4 (decreased number in the plasma membrane) or an impairment of its intrinsic activity in muscle and adipose tissue or both [12, 13] . The mechanisms underlying hyperglycaemia-induced liver insulin resistance have not yet been determined.
Phlorizin treatment of diabetic rats, by inhibiting renal tubular glucose reabsorption, leads to near normal fed plasma glucose levels without significantly altering low fed plasma insulin levels. Such treatment has been shown to restore insulin action not only in peripheral tissues [9] [10] [11] , but also in liver [10] of insulin-deficient animals. In the present study, we administered phlorizin as a continuous subcutaneous infusion to streptozotocimdiabetic rats for 18 days. Then, we examined whether mere correction of hyperglycaemia by glucuresis reversed the abnormal expression of genes involved in hepatic glucose metabolism. This was achieved by measuring mRNA levels of glycolytic [glucokinase (GK) and L-type pyruvate kinase (L-PK)] and gluconeogenic [phosphoenolpyruvate carboxykinase (PEPCK)] enzymes, and of the glucose transporter isoform (GLUT 2) in liver of phlorizin-treated rats.
Materials and methods

Animals and experimental design
Male Wistar rats (8 weeks old; 224 -+ 1 g) were purchased from IFFA Credo (L'Abresle, France). All rats received ad libitum a standard laboratory chow (Extralabo M-25; Ets. Pietrement, Provins, France; % of total energy (calories/calories): 60 % carbohydrate, 11% fat, 29 % protein) and were housed in individual cages at a constant temperature (22 ~ A 12-h-light-dark cycle was set up (lights on 03.00 15.00 hours) with liver samples taken during the absorptive state of the animals (between 08.00-10.00 hours) at the end of the study.
The animals were divided into three experimental groups: nondiabetic control rats (C; n = 5); untreated diabetic rats (D; n --5); diabetic rats treated with phlorizin (PHL; n =5). Non-ketotic diabetes was induced by an i. v, injection of streptozotocin (45 mg/kg body weight) into a tail vein. Streptozotocin (Sigma, St Louis, Mo., USA) was dissolved in cold 0.1 mol/1 citrate buffer (pH 4.5) immediately before use. Control animals received only the buffer. Five days after injection of streptozotocin, the diabetic rats were assigned to untreated or treated groups. The two groups of diabetic rats were matched for pre-treatment body weight (D: 249_+3 g, PHL: 240_+ 4 g, p > 0.05) and for pre-treatment fed plasma glucose levels (D: 25.6 _+ 1.4 retool/l, PHL: 26.2 _+ 1.7 mmol/1,p > 0.05). The treated group received phlorizin (Sigma, 0.4 g/kg body weight per day, dissolved in propylene glycol) as a subcutaneous injection in two equally divided doses during the first 3 days, and thereafter as a continuous subcutaneous infusion via an implantable mini-pump. The osmotic mini-pump allowed for continuous inhibiton of renal tubular resorption of glucose and maintenance of a tighter glycaemic control. This pump (Alzet model 2 ML1; Alza Corp., Palo Alto, Calif., USA) was implanted under light ether anaesthesia, removed after 1 week of use and replaced by a second pump to obtain a 18-day phlorizin exposure period. Animals from the three groups were handled frequently to minimize non-specific reactions that could occur during blood sampling.
On several occasions, tail vein blood was collected from conscions fed animals for determination of piasma glucose and insulin levels. Plasma glucagon concentrations were also measured on days 5 and 17 of the study. Samples were collected into ice-cold heparinized tubes which were rapidly centrifuged. Plasma glucagon was protected from degradation by a trypsin inhibitor, Iniprol (Laboratoires Choay, Paris, France).
After 18 days of treatment, animals were killed between 08.00-10.00 hours (i. e. in the absorptive state). The liver was immediately removed, frozen in liquid nitrogen and stored at -80~ for subsequent mRNA extraction, crude membrane preparation and enzyme activity measurement. 293 heating at 95~ for 2 min. RNA was then size-fractionated by 1% agarose gel electrophoresis, transferred to a Hybond-N membrane (Amersham Int., Amersham, Bucks, UK) and cross-linked by ultraviolet irradiation. The integrity and relative amounts of RNA were assessed by methylene blue staining of the blot.
The GK, L-PK, PEPCK and GLUT 2 cDNA probes were kindly supplied by Drs. R Iynedjian [15] , A.Kahn [16] , R.W Hanson [17] and B. Thorens [18] , respectively. Probes were labelled with 32p using the Megaprime labelling system kit (Amersham). Hybridizations with L-PK, PEPCK or GLUT 2 probes were carried out in medium containing denatured salmon sperm DNA (0.3mg/ml), 42% deionized formamide, 7.5 % dextran sulphate, 8 x Denhardt's solution (Denhardt 1 x:0.2g/1 polyvinylpyrrolidone, 0.2g/1 bovine serum albumin, 0.2 g/1 ficoll 400), 40 mmol/1-Tris/HCl (pH 7.5), 0.1% sodium pyrophosphate and 1% sodium dodecyl sulphate (SDS) at 42~ overnight. Hybridization with GK probe was performed in 3 X sodium saline phosphate ethylenediamine tetraacetic acid (SSPE) buffer, 1% SDS, 1% glycine, 0.2% ficoll, 0.2% polyvinylpyrrolidone, 10 % polyethylene glycol and denaturated salmon sperm DNA (0.2 mg/ml) at 65~ overnight. The membrane was washed two times for 30 min in 2 • sodium saline citrate (SSC) buffer/0.1% SDS at 42 ~ and once for 15-30 rain in 0.14).5 • SSC/0.1% SDS at 55~ (PEPCK, GLUT 2) or 65~ (L-PK). The membrane hybridized with GK was washed two times for 20rain in 2 x SSPE/1% SDS and once for 15 min in 0.5 x SSPE/1% SDS at 65 ~ The filters were then exposed to Fuji X-Ray films for 7~t8 h at -80 ~ with intensifying screens.
Intensity of the mRNA bands on the blots was quantified by scanning densitometry (Hoefer, San Francisco, Cafif., USA).
Membrane preparatton and Western blot analysis
Total liver membranes were prepared according to Thorens et al. [18] . Briefly, tissue ( _+ 200 mg) was homogenized with 10 strokes of a motor-driven Teflon pestle in 20volumes of 0.25 molll sucrose/25 mmol/l Hepes buffer (pH 7.4) containing 3 mmol/l dithiothreitol, 0.26 U/ml aprotinin, 0.1 mmol/1 phenylmethylsulphonyl fluoride. This homogenate was centrifuged for 10 min at 8000 g and the supernatant was centrifuged again for 20 rain at the same speed. The cytosol was then centrifuged for 40 rain at 150000 g and the membrane pellet was resuspended in phosphate-buffered saline (8 g/! NaC1, 0.2 g/1 KC1, 1.44 g/1 NaH2PO4, 0.24 g/1 KH2PO4; pH 7.4). Protein content was measured by the method of Bradford [19] (BioRad, Munich, FRG), using bovine serum albumin as standard.
Equal amounts of membrane proteins (100 pg) were solubilized in Laemmli buffer [20] , submitted to a 12 % SDS-PAGE and electrophoretically transferred to nitrocellulose membranes (Schleicher & SchuelI, Dassel, FRG). Rainbow protein markers were used as molecular weight standards and also to assess the effidency of the transfer. Filters were then processed as previously described [18] . After blocking, the membranes were incubated with a 10-2 dilution of anti-peptide antibody directed against GLUT 2 (a gift from Dr B. Thorens). The detection was performed with 0.1 gCi/m112SI-protein A, followed by autoradiography and subsequent quantification by scanning densitometr3:
Measurement of enzyme activities
RNA extraction and Northern blot analysis
Total RNA was isolated by a single extraction with an acid guanidinium thiocyanate-phenol-chloroform mixture [14] . The concentration of RNA was determined by absorbance at 260 nm. All samples had a 260/280 absorbance ratio of about 2. For Northern blot analysis, RNA (30~tg) was denaturated in a solution containing 2.2 mmot/1 formaldehyde and 50 % formamide (volume/volume) by All enzyme activities were carried out at 37 ~ GK (EC 2.7.1.1) activity was determined using a spectrophotometric assay [21J by subtracting the hexokinase activity measured at 0.5 mmot/1 glucose from the activity measured at 100 mmol/1 glucose. Results were expressed as lamol NADH produced, rain-1. g liver-1. L-PK (EC 2.7.1.40) was measured according to Blair et al. [22] at a subsaturating concentration of phosphoenolpyruvate (PEP) (1.3 mmol/1) (active form of the enzyme) and at saturating concentration of PEP (6.6 mmol/1) (maximal activity of the enzyme). Results were expressed as pmol NADH 
Analytical procedures
Plasma glucose was measured by a glucose oxidase method (Peridochrom; Boehringer-Mannheim, Mannheim, FRG). Plasma insulin was determined by a double-antibody radioimmunoassay, using rat insulin as standard (Novo Research Institute, Bagsvaerd, Denmark). Plasma glucagon was measured by a radioimmunoassay using a charcoal separation step and the antiserum 04A, which is considered to be specific for pancreatic glucagon (Dr. R. H. Unger, Dallas, Tx., USA).
Statistical analysis
Results are given as the mean _+ SEM for the indicated number of rats. Comparisons between control, diabetic, and phlorizin-treateddiabetic rats were carried out by analysis of variance followed by the Newman-Keuls test for multiple comparisons [24] . Student's t-test for paired data was used to evaluate the time course of phlorizin effect on plasma insulin levels. Differences were considered statistically significant atp < 0.05.
Results
Diabetic rats gained weight at a much lower rate than controls. This growth retardation was not improved by phlorizin treatment (Table 1) .
Average plasma glucose levels in fed diabetic rats were above 25 retool/1 and their plasma insulin levels were decreased by more than 50 %. Phlorizin administration to diabetic rats resulted in a normalization of plasma glucose concentrations ( Table 1 ). The correction of hyperglycaemia was observed as early as after 5 days of treatment and persisted until the end of the experiment. This effect was not due to a rise in plasma insulin levels, which did not change throughout the study (day 5 vs day 17, p > 0.05 by paired t-test) and remained low in fed phlorizin-treated diabetic rats (Table 1) . Plasma glucagon levels were increased by 75 % in diabetic animals. This rise was totally prevented by 17days of phlorizin administration ( Table 1 ). The glucagonqowering effect induced by phlorizin was not observed after 5 days of treatment (data not shown).
Protracted hyperglycaemia in diabetic rats was associated with overt polydipsia: their daily fluid consumption was four-fold greater than in control rats (D: 188 + 12 ml/day vs C: 40 + 4 ml/day, p < 0.01). Although reduced, fluid intake in phlorizin-treated diabetic rats (107 + 2 ml/day) remained two-fold higher than in controls (p < 0.01), which probably reflects the increased urinary losses of glucose produced by the treatment.
To determine whether relief of hyperglycaemia by phlorizin glucuresis was associated with altered expression of genes involved in key steps of hepatic glucose metabolism, we measured mRNA levels of glycolytic and gluconeogenic enzymes, and of the GLUT 2 transporter isoform. Yields of total RNA in liver did not differ between the three groups (C: 4.2+0.4mg/g; D: 5.1 _+0.6 rag/g, PHL: 4.7-+0.3 mg/g). The abundance of mRNAs encoding the glycolytic enzymes, L-PK and GK, was assessed by Northern blot analysis. L-PK and GK m R N A transcripts (3.2 and 2.4 kilobases (kb), respectively) were barely detectable in diabetic liver (Fig. 1) . Quantification of autoradiographic signals showed that L-PK and GK mRNAs were decreased, respectively by 70 % and 90%, in diabetic rats compared with control rats (Fig. 2) . The activities of L-PK (at submaximal and maximal PEP concentrations) and G K were lowered accordingly (Table 2) . Phlorizin treatment given to streptozotocin-diabetic rats for 18 days did not modify L-PK m R N A and activity. However, this treatment restored GK m R N A and activity to 41% and 43 % of control levels, respectively. Compared to untreated diabetic rats, GK m R N A and activity were increased 20-and five-fold, respectively, in liver of phlorizin-treated rats ( Figs. 1 and 2 , Table 2 ). Diabetes induced a 10-fold rise in m R N A levels of the gluconeogenic enzyme, PEPCK (Figs. 1 and 2) , and a 2.2-fold rise in the enzyme activity, as compared to control rats ( Table 2 ). Phlorizin administration decreased PEPCK m R N A to values not significantly different from those in control rats, while P E P C K activity remained only slightly higher than that in controls (50 % ) (Figs. 1 and 2, Table 2 ).
Glucose transport in liver is mostly mediated by G L U T 2, the glucose transporter isoform which is involved in either net glucose uptake or release depending on the prevailing metabolic conditions. Examination of G L U T 2 m R N A transcript (2.8 kb) abundance on Northern blots indicated that levels of these liver transcripts were increased by 50 % in diabetic liver (Figs. 1 and 2) . The amount of G L U T 2 protein was measured by Western blot analysis in crude liver membranes. G L U T 2 protein levels were slightly increased by diabetes (Table 2) . Altered abundance of G L U T 2 m R N A and protein was corrected upon treatment of diabetic rats with phlorizin.
Discussion
We confirmed that chronic administration of phlorizin to streptozotocin-diabetic rats normalized their fed plasma glucose levels without significantly altering their fed plasma insulin levels. We further showed that this treatment also corrected their fed hyperglucagonaemia and partially corrected the abnormal expression of genes involved in hepatic glucose metabolism.
In a previous study, no change in basal plasma glucagon levels was observed in diabetic rats after chronic phlorizin treatment [25] . However, the partially pancreatectomized rat model was used which did not exhibit absolute hyperglucagonaemia [25] due tO a 70 % decrease in its pancreatic glucagon content [5] . In the present work, hyperglucagonaemia is clearly present in streptozotocin-diabetic rats. Several mechanisms could theorically contribute to the glucagon-lowering effect induced by phlorizin in these animals. First, a direct action of phlorizin on alpha cells. This is unlikely, since direct perfusion of the drug into the isolated pancreas did not alter glucagon secretion [6] . Second, the circulatory arrangement within islets exposes alpha cells to the highest circulating insulin concentrations in the body and facilitates a role for insulin as an in-hibiting factor for glucagon release [26] . Fed plasma insulin concentrations, measured throughout this study, did not significantly increase in diabetic rats treated with phlorizin. This is in agreement with previous reports which further showed that phlorizin did not alter insulin secretion in response to a meal or an i.v. glucose bolus in similarly mildly insulin-deficient rats [7, 9, 10, 25] . However, minute restoration of glucose induced-insulin release cannot be excluded. Some restoration of beta-cell function, barely detectable by the tests mentioned above, has been observed during hyperglycaemic clamp studies performed in partially pancreatectomized rats chronically treated with phlorizin [7] . It should be emphasized, however, that in these studies, the plasma insulin response remained small, when considered in absolute terms, and did not exceed 15 % of that in control rats [7] . Third, it has been suggested that alpha cells have a glucose-sensing system that functions independently of insulin and beta cells and that this system may be attenuated by chronic hyperglycaemia. A rise in glucose concentration does not suppress glucagon release in the insulin-deficient diabetic state [27] , which it normally does. Strong evidence that diabetic alpha-cell "blindness" to glucose can be reversed, despite continuing insulin deficiency, by mere correction of hyperglycaemia with phtorizin, has been obtained in totally insulin-deprived dogs [6] . The normal decrease in plasma glucagon levels in response to a physiological rise in glycaemia was restored in phlorizin-treated (normoglycaemic) diabetic dogs [6] . Such a mechanism is likely to play a determining role in the normalization of glucagonaemia, as shown in the present study in long-term phlorizin-treated diabetic rats.
It has been reported that chronic administration of glucagon to normal rats modified a number of hepatic enzyme activities (including L-PK and PEPCK), mainly by affecting enzyme levels [28] . Since chronic hyperglucagonaemia opposes the suppressive effect of insulin on hepatic glucose production [29] and since liver insulin resistance in diabetic rats has been shown to be corrected by phlorizin treatment [t0], we examined whether such a treatment could reverse the abnormal expression of several genes involved in key enzymes of hepatic glucose metabolism. Phlorizin administration to diabetic rats partially restored GK mRNA levels (40 % of control values; 20-fold rise compared with untreated diabetic rats), reversed PEPCK mRNA levels, but had no effect on L-PK mRNA levels. All these effects of phlorizin may be related to hormonal changes (mainly lowering of hyperglucagonaemia) or correction of hyperglycaemia or both. Evidence has been presented that the mRNA levels of glycolytic enzymes (GK and L-PK) are increased by insulin and decreased by glucagon both in vivo [30] [31] [32] and in vitro [32] [33] [34] . In cultured hepatocytes, the inhibitory effect of glucagon dominates over the stimulatory effect of insulin in the control of the expression of these enzymes [33, 34] . Thus, correction of hyperglucagonaemia may allow, in the presence of low -but still detectable -plasma insulin levels, a partial re-induction of GK mRNA in the liver of phlorizin-treated diabetic rats. In contrast to GK, whose transcription is glucose-independent [33] , L-PK expression requires the presence of high glucose levels for its S. M. Brichard et al.: Phlorizin effects on liver gene expression induction by insulin [34] . The lack of L-PK re-induction in phlorizin-treated diabetic rats could, therefore, be explained by the lowering of glycaemia, which prevented the effect due to the correction of hyperglucagonaemia.
Liver PEPCK gene expression is increased by glucagon and decreased by insulin both in vivo [35] and in vitro [32] , and this regulation appears to be mainly glucose-independent [32] . It was first shown in hepatoma cells that the inhibitory effect of insulin on PEPCK transcription was predominant over the stimulatory effect of cAMP (second messenger of glucagon) [36] . Howevel, hepatoma cells do not possess the enzyme pattern and hormone responsiveness of normal liver cells. In a more physiological model, namely primary cultures of hepatocytes, it was recently demonstrated that glucagon was predominant over insulin in the regulation of PEPCK expression [37] . Thus, the lowering of hyperglucagonaemia, again, may be the major mechanism which could account for the reduction of PEPCK expression in phlorizin-treated mildly insulindeficient rats. One cannot preclude, however, that the reversal of GK and PEPCK mRNAs would have been less pronounced if more insulinopoenic rats were used.
Alterations in enzyme activities of treated diabetic rats paralleled changes in mRNA concentrations. In the fed state, PEPCK activity was however only partially restored, whereas PEPCK mRNA levels were decreased to values not significantly different from those in control rats. This may be due to the difference in half-lives, since it has been shown that, during refeeding, PEPCK activity decays more slowly (tl/2 ~ 6 h) [38] than the corresponding mRNA (t~/2 = 1 h) [35] .
Although glycolytic and gluconeogenic fluxes were not measured in the present study, changes in enzyme activities are likely to reflect changes in their actual catalytic rates. Indeed, GK and PEPCK activities are not regulated by phosphorylation/dephosphorylation or by allosteric mechanisms. L-PK activity is markedly decreased by glucagon-mediated phosphorylation [22] . The active form of L-PK, which takes into account the phosphorylation state of the enzyme [22] , has been measured in the current study. The changes in active form of L-PK paralleled the changes in maximal activity. On this basis, the present data strongly suggest that phlorizin treatment may partially shift liver gluconeogenesis into glycolysis in diabetic rats.
Glucose transport is not considered to be the ratelimiting step of hepatic glucose metabolism, and the major transporter GLUT 2 is involved in either net glucose uptake or release, depending upon the prevailing metabolic conditions [39] . In agreement with some [40, 41] , but not all [42] , previous reports, a 50 % rise in GLUT 2 mRNA was observed in the liver of streptozotocin-diabetic rats. GLUT 2 protein was also slightly increased. This could contribute to the enhanced hepatic glucose output from diabetic liver [40] . Altered abundance of GLUT 2 mRNA and protein was corrected by phlorizin treatment of diabetic rats. In vivo experiments with primary cultured hepatocytes have shown that GLUT 2 gene was increased by high glucose levels [43, 44] and decreased by insulin [44] . Evidence that such a regulation also occurred in vivo has recently been provided [44, 45] . The potential regulatory role of glucagon on GLUT 2 has not yet been in-vestigated. However, correction of hyperglycaemia in the presence of low circulating insulinaemia may contribute to understanding the effects produced by phlorizin treatment on GLUT 2 expression in diabetic rats.
In conclusion, elimination of chronic hyperglycaemia by phlorizin glucuresis may allow some metabolic compensation in diabetic liver. Long-term phlorizin treatment of diabetic rats may induce a partial shift of the predominating gluconeogenesis, associated with hepatic glucose overproduction, into glycolysis, by correction of impaired pre-translational regulatory mechanisms. This could be essentially mediated through improvement of pancreatic alpha-cell function and subsequent lowering of hyperglucagonaemia. These observations suggest that glucagonstimulated hepatic glucose production results, in part, from glucose toxicity and reinforce the need for tight glycaemic control in diabetes.
